PARP inhibitor clinical trials for prostate cancer were recently reviewed and analyzed extensively, so here, we will summarize several major trials for four PARP inhibitors that have been tested in mCRPC: Olaparib, Rucaparib, Niraparib, and Talazaporib [97,98,99]. The gene discussed is PARP1; the disease is prostate carcinoma.